Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
C12N-005/06
C12N-015/00
A61K-039/395
C12P-021/04
C12P-021/08
C07K-016/00
출원번호
UP-0724040
(2007-03-13)
등록번호
US-7777017
(2010-09-06)
발명자
/ 주소
Stinson, Jeffrey R.
Schuman, Richard F.
Mond, James Jacob
Lees, Andrew
Fischer, Gerald Walter
출원인 / 주소
Biosynexus Incorporated
대리인 / 주소
Lahive & Cockfield, LLP
인용정보
피인용 횟수 :
7인용 특허 :
33
초록▼
The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, h
The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.
대표청구항▼
What is claimed is: 1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody light chain, or variable region thereof, the light chain or variable region comprising the sequence as set forth in residues 1-106 of SEQ ID NO:10. 2. An isolated nucleic acid
What is claimed is: 1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody light chain, or variable region thereof, the light chain or variable region comprising the sequence as set forth in residues 1-106 of SEQ ID NO:10. 2. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody heavy chain, or variable region thereof, the heavy chain or variable region comprising the sequence as set forth in residues 1-123 of SEQ ID NO:12. 3. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody light chain, or variable region thereof, the light chain or variable region comprising the complementarity determining regions (CDRs) from the antibody light chain variable region sequence set forth as SEQ ID NO:10. 4. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody heavy chain, or variable region thereof, the heavy chain or variable region comprising the complementarity determining regions (CDRs) from the antibody heavy chain variable region sequence set forth as SEQ ID NO:12. 5. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody light chain variable region amino acid sequence and a monoclonal antibody heavy chain variable region amino acid sequence selected from the group consisting of SEQ ID NOs. 10 and 12, SEQ ID NOs. 10 and 17, and SEQ ID NOs. 16 and 12. 6. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody light chain, or variable region thereof, the light chain or variable region thereof comprising the complementary determining regions (CDRs) from the light chain of the monoclonal antibody produced by the hybridoma deposited at the ATCC under Accession number PTA-3644. 7. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody light chain variable region comprising CDRs from SEQ ID NO: 10 and a monoclonal antibody heavy chain variable region comprising CDRs from SEQ ID NO: 12. 8. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody light chain variable region comprising CDRs from SEQ ID NO: 10 and a monoclonal antibody heavy chain variable region comprising CDRs from SEQ ID NO: 17. 9. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody light chain variable region comprising CDRs from SEQ ID NO: 16 and a monoclonal antibody heavy chain variable region comprising CDRs from SEQ ID NO: 12. 10. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody light chain variable region amino acid sequence set forth in SEQ ID No: 10 and a monoclonal antibody heavy chain variable region amino acid sequence set forth in SEQ ID No:12 or 17. 11. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody heavy chain variable region amino acid sequence set forth in SEQ ID NO:12 and a monoclonal antibody light chain variable region amino acid sequence set forth in SEQ ID No:10 or 16. 12. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the M120 monoclonal antibody heavy chain, or variable region thereof, produced by the hybridoma deposited at the ATCC under Accession number PTA-3644. 13. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the M120 antibody light chain, or variable region thereof, produced by the hybridoma deposited at the ATCC under Accession number PTA-3644. 14. An isolated vector comprising a nucleotide sequence encoding a monoclonal antibody light chain, or variable region thereof, the light chain or variable region comprising the sequence as set forth in residues 1-106 of SEQ ID NO:10. 15. An isolated vector comprising a nucleotide sequence encoding a monoclonal antibody heavy chain, or variable region thereof, the heavy chain or variable region comprising the sequence as set forth in residues 1-123 of SEQ ID NO:12. 16. An isolated vector comprising the nucleic acid molecule of claim 3. 17. The isolated vector of claim 16, further comprising a nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody heavy chain, or variable region thereof, comprising the complementarity determining regions (CDRs) from the antibody heavy chain variable region sequence set forth as SEQ ID NO: 12. 18. An isolated vector comprising the isolated nucleic acid molecule of claim 5. 19. An isolated cell line comprising a first vector, said first vector comprising the vector of claim 16. 20. The isolated cell line of claim 19, further comprising a second vector, said second vector comprising an isolated nucleotide sequence encoding comprising the complementarity determining regions (CDRs) from the antibody heavy chain variable region sequence set forth as SEQ ID NO:12. 21. An isolated cell line comprising the vector of claim 18. 22. An isolated nucleic acid molecule comprising the nucleotide sequence set forth as SEQ ID NO:11. 23. An isolated nucleic acid molecule comprising the nucleotide sequence set forth as SEQ ID NO:13. 24. A method of producing a monoclonal antibody, or an antigen-binding fragment thereof, comprising culturing the cell line of claim 20 under conditions such that the antibody or antigen-binding fragment is produced, and isolating said antibody or antigen-binding fragment from the cell line or culture. 25. A method of producing a monoclonal antibody, or an antigen-binding fragment thereof, comprising culturing the cell line of claim 21 under conditions such that the antibody or antigen-binding fragment is produced and isolating said antibody or antigen-binding fragment from the cell line or culture. 26. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a monoclonal antibody heavy chain, or variable region thereof, the heavy chain or variable region thereof comprising the complementary determining regions (CDRs) from the heavy chain of the monoclonal antibody produced by the hybridoma deposited at the ATCC under Accession number PTA-3644. 27. An isolated vector comprising a nucleotide sequence encoding a monoclonal antibody light chain, or variable region thereof, the light chain or variable region thereof comprising the sequence set forth in residues 1-106 of SEQ ID NO:10 and a heavy chain, or variable region thereof, the heavy chain or variable region thereof comprising the sequence set forth in residues 1-123 of SEQ ID NO:12. 28. An isolated vector comprising the isolated nucleic acid molecule of claim 10. 29. An isolated vector comprising the isolated nucleic acid molecule of claim 11. 30. An isolated cell line comprising the vector of claim 28. 31. An isolated cell line comprising the vector of claim 29.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (33)
Carozzi Nadine B. (Raleigh NC) Koziel Michael G. (Cary NC), Antibodies which bind to insect gut proteins and their use.
Frank Robert (Strasbourg FRX) Klein Jean P. (Breuschwickersheim FRX) Ackermans Fabienne (Brussels BEX) Bazin Herv (Brussels BEX), Conjugate constituted from a wall adhesin of S. mutans of proteinic nature and from a polysaccharide of 상세보기
Carroll Sean B. (Cottage Grove WI) Firca Joseph R. (Vernon Hills IL) Pugh Charles (Madison WI) Padhye Nisha V. (Madison WI), Conjugates for the prevention and treatment of sepsis.
Marburg Stephen (Metuchen NJ) Tolman Richard L. (Warren NJ) Jorn Deborah A. (Metuchen NJ), Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogeni.
Hk Magnus (Birmingham AL) Jnsson Klas (Studentvgen SEX) Lindberg Kjell M. (Kornvgen SEX) Signs Christer (Hamnesplanaden SEX), DNA encoding a fibronectin binding protein as well as its preparation.
Burnham Martin Karl Russel,GBX ; Chopra Ian,GBX ; Critchley Ian Alfred,GBX ; Knowles David Justin Charles,GBX, Fibronectin binding protein polypeptides.
Gristina Anthony G. (Reston VA) Myrvik Quentin N. (Caswell Beach NC), Method and compositions for the direct concentrated delivery of passive immunity.
Emery Daryll A. (Willmar MN) Straub Darren E. (Willmar MN) Huisinga Richard (Willmar MN), Method of priming an immune response in a one-day old animal.
Gristina Anthony G. (11605 Deer Forest Rd. Reston VA 22094) Myrvik Quentin N. (404 Palmetto Dr. Caswell Beach NC 28465), Methods and compositions for the direct concentrated delivery of passive immunity.
Blackburn Michael Neal ; Church William Robert ; Feuerstein Giora Zeev ; Gross Mitchell Stuart ; Nichols Andrew John ; Padlan Eduardo Agustin ; Patel Arunbhai Haribhai ; Sylvester Daniel Robert, Nucleic acids encoding immunoglobulin domains.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Fournier Jean-Michel (Paris FRX) Bouvet Anne (Paris FRX) Boutonnier Alain (Paris FRX), Process for the preparation of capsular polysaccharides of staphylococci, the polysaccharides obtained, uses of these po.
d\Hinterland Lucien D. (Castres FRX) Normier Grard (Castres FRX) Pinel Anne-Marie (Castres FRX) Durand Jacques (Castres FRX), Vaccinal complex containing a specific antigen and vaccine containing it.
Lees, Andrew, Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines.
Lees, Andrew, Activation of polysaccharides via the cyanylating agent, 1-cyanobenzotriazole (1-CBT), in the preparation of polysaccharide/protein conjugate vaccines.
Lees, Andrew, Activation of polysaccharides via the cyanylating agent, 1-cyanoimidazole (1-Cl), in the preparation of polysaccharide/protein conjugate vaccines.
Lees, Andrew, Activation of polysaccharides via the cyanylating agent, 2-cyanopyridazine-3(2H)-one (2-CPO), in the preparation of polysaccharide/protein conjugate vaccines.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.